Search By

Format
Articles (614)Events (33)News (4148)Interviews (79)
Publication Date
Last 3 months Last 6 months Last 12 months All Time

614 Results

Search By

ArticlesEventsNewsInterviews

Regulatory Landscape

470 FDA Warning Letters in 2025: The Lab Compliance Patterns You Can't Afford to Ignore

Learn the lab compliance patterns behind 470 FDA warning letters in 2025 and what every regulated lab must do differently.

Vaibhavi M. | May 04, 2026

Regulatory Landscape

Cracking The SOP Compliance Problem: What Quality Leaders Must Know!

Uncover root causes of pharma SOP non-compliance, FDA 483 risks, and practical strategies to build compliance-friendly systems.

Simantini Singh Deo | May 04, 2026

Regulatory Landscape

EMA's 2025–2027 Quality Roadmap: What Pharma Companies Need To Know About The GMDP Work Plan

EMA's 2025 2027 GMDP Work Plan 10 GMP revisions, Annex 22 AI, supply chain resilience and what pharma must prepare for now.

Vaibhavi M. | May 04, 2026

Regulatory Landscape

EU GMP Explained: A Practical Guide to EudraLex Volume 4

A practical guide to EudraLex Volume 4 for pharma manufacturers EU GMP structure, key annexes, compliance tips and inspection readiness explained.

Vaibhavi M. | May 04, 2026

Regulatory Landscape

How Schedule M Expects Pharma Companies to Handle Complaints and Adverse Reactions

How Schedule M 2023 Section 6 defines complaint handling, ADR reporting and pharmacovigilance obligations for pharma manufacturers.

Vaibhavi M. | May 04, 2026

Regulatory Landscape

Understanding FDA 21 CFR Part 210: What It Means For Drug Manufacturing And How To Stay Compliant?

Understand what FDA 21 CFR Part 210 means for drug manufacturing, who must comply, and how to stay compliant.

Simantini Singh Deo | May 02, 2026

Regulatory Landscape

A Practical Guide To Loan Licensing And Contract Manufacturing In Schedule M 2023

Learn how Schedule M 2023 Section 9 governs loan licensing and contract manufacturing with strict GMP controls.

Simantini Singh Deo | May 02, 2026